Panacos Pharmaceuticals 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2006
PANACOS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
134 Coolidge Avenue
Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (617) 926-1551
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
ITEM 8.01 OTHER EVENTS
On December 19, 2006, Panacos Pharmaceuticals, Inc. (the Company) announced first cohort results for its Phase 2b clinical trial of bevirimat (previously designated PA-457), the Companys lead drug candidate for the treatment of HIV. The press release regarding this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.